Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as single or multiple tablets) or HU6 300 mg twice daily (BID) (supplied as two 150 mg tablets) or HU6 150 mg drug substance in a capsule × 3 (450 mg total dose) QD or HU6 150 mg granulated blend in a capsule × 3 (450 mg total dose) QD.

NCT Number	NCT07170189
Lead Sponsor	Rivus Pharmaceuticals, Inc.
Conditions	Overweight
Enrollment	59 participants
Start Date	2025-10-13
Primary Completion	2025-12-04 (estimated)
Study Completion	2025-12-04 (estimated)
Updated on ClinicalTrials.gov	2026-01-21